Logo image of ZNTL

ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Fundamental Analysis

NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD

2.07  +0.05 (+2.48%)

After market: 2.07 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZNTL. ZNTL was compared to 571 industry peers in the Biotechnology industry. While ZNTL has a great health rating, there are worries on its profitability. ZNTL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZNTL had negative earnings in the past year.
In the past year ZNTL has reported a negative cash flow from operations.
ZNTL had negative earnings in each of the past 5 years.
ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

ZNTL's Return On Assets of -39.78% is in line compared to the rest of the industry. ZNTL outperforms 56.43% of its industry peers.
The Return On Equity of ZNTL (-50.60%) is better than 65.36% of its industry peers.
Industry RankSector Rank
ROA -39.78%
ROE -50.6%
ROIC N/A
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -50K -100K -150K -200K

More info and screens

7

2. Health

2.1 Basic Checks

ZNTL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ZNTL has been increased compared to 5 years ago.
ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -2.73, we must say that ZNTL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.73, ZNTL is in line with its industry, outperforming 48.93% of the companies in the same industry.
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.73
ROIC/WACCN/A
WACCN/A
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

ZNTL has a Current Ratio of 7.29. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.29, ZNTL is doing good in the industry, outperforming 68.93% of the companies in the same industry.
A Quick Ratio of 7.29 indicates that ZNTL has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.29, ZNTL is doing good in the industry, outperforming 69.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 7.29
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

ZNTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.06%, which is quite impressive.
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.08% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.09%
EPS Next 2Y19.93%
EPS Next 3Y13.23%
EPS Next 5Y12.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZNTL. In the last year negative earnings were reported.
Also next year ZNTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

ZNTL's earnings are expected to grow with 13.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.93%
EPS Next 3Y13.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZNTL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (2/28/2025, 8:00:02 PM)

After market: 2.07 0 (0%)

2.07

+0.05 (+2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners93.32%
Inst Owner Change-8.49%
Ins Owners15%
Ins Owner Change27%
Market Cap147.53M
Analysts77.65
Price Target6.4 (209.18%)
Short Float %8.09%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-44.57%
Max EPS beat(2)39.67%
EPS beat(4)3
Avg EPS beat(4)28.36%
Min EPS beat(4)-44.57%
Max EPS beat(4)117.9%
EPS beat(8)5
Avg EPS beat(8)8.21%
EPS beat(12)7
Avg EPS beat(12)7.99%
EPS beat(16)8
Avg EPS beat(16)3.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34%
PT rev (3m)-34%
EPS NQ rev (1m)10.94%
EPS NQ rev (3m)10.94%
EPS NY rev (1m)1.94%
EPS NY rev (3m)1.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)1.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.64
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-2.59
EYN/A
EPS(NY)-2.61
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.41
OCFYN/A
SpS0.57
BVpS4.97
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.78%
ROE -50.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.1%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 7.29
Altman-Z -2.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)450.59%
Cap/Depr(5y)428.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.11%
EPS Next Y47.09%
EPS Next 2Y19.93%
EPS Next 3Y13.23%
EPS Next 5Y12.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.64%
EBIT Next 3Y7.84%
EBIT Next 5YN/A
FCF growth 1Y-2.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.09%
OCF growth 3YN/A
OCF growth 5YN/A